Summary: New research points to a promising strategy for correcting dopamine imbalances in the brain by using a drug that blocks kappa opioid receptors (KOR). In mouse models carrying a rare DAT Val559 mutation that causes abnormal dopamine leakage, KOR antagonists reduced transporter-mediated leak, restored normal dopamine dynamics, and corrected related behavioral impairments.
This targeted approach could lead to safer treatments for conditions linked to disrupted dopamine signaling—such as ADHD, bipolar disorder, autism spectrum disorder, and other neuropsychiatric illnesses—because the therapy normalized function in affected animals while producing little effect in mice with normal dopamine transporters, suggesting a lower risk of side effects.
Key Facts:
- Targeted action: KOR antagonism reduces anomalous dopamine transporter (DAT) leak in animals expressing the DAT Val559 variant.
- Behavioral restoration: Blocking KOR corrected cognitive and compulsive-like behaviors in mutant mice without altering behavior in control animals.
- Potential clinical relevance: The findings support KOR antagonists as a candidate approach for treating multiple disorders that involve altered dopamine signaling.
Source: FAU
Overview of dopamine and brain function: Dopamine, synthesized from the amino acid tyrosine, is essential for motor control, motivation, mood regulation, attention, and memory. Tight regulation of dopamine signaling is critical: after dopamine is released at synapses, specialized proteins called dopamine transporters (DAT) rapidly remove it to limit signal duration and preserve precise neural communication.
Disruptions in dopamine signaling have been implicated in many neuropsychiatric disorders, including ADHD, schizophrenia, bipolar disorder, autism spectrum disorder, and substance use disorders. Current therapies often act broadly to boost or suppress dopamine — for example, stimulant medications prescribed for ADHD increase dopamine but carry risks such as side effects and potential for abuse.
To identify more precise interventions, researchers at Florida Atlantic University and collaborators explored whether modulating kappa opioid receptors could correct specific transporter-related defects that perturb dopamine homeostasis.
Kappa opioid receptors and dopamine regulation: KORs are a subtype of opioid receptor expressed on dopamine neurons. When activated, KORs can lower synaptic dopamine by decreasing release and promoting surface expression of DAT, thereby enhancing clearance. Instead of stimulating KOR, the investigators tested the opposite strategy: using KOR antagonists to block the receptor and examine whether that would normalize DAT function in a disease model.
The DAT Val559 variant, a rare genetic change found in some individuals diagnosed with ADHD, ASD, or bipolar disorder, converts the transporter into a leakier form that passively releases dopamine into the synapse rather than efficiently clearing it. This chronic, low-level leak blunts the rapid, phasic dopamine signals that are critical for attention, reward processing, and emotional regulation — a pattern distinct from the sharp dopamine surges that drive euphoria and addiction.
Using mouse models engineered to express DAT Val559, the research team administered a long-acting KOR antagonist. The drug reduced surface expression of the mutant transporter where it meets extracellular dopamine, limiting the anomalous efflux and restoring more normal dopamine signaling. Importantly, KOR antagonism corrected several behavioral abnormalities tied to attention and compulsivity in these mice.
The study’s results indicate that when DAT expression, phosphorylation, or trafficking is altered, dopamine availability and timing are disrupted, producing traits clinicians describe as inattentiveness or compulsivity and changing emotional reactivity. By blocking KOR, researchers were able to reverse these molecular and behavioral disturbances in the animal model.
Although the DAT Val559 mutation itself is rare, DAT function is highly sensitive to many intracellular regulatory pathways. The authors note that disruptions of those pathways — or other mechanisms that alter dopamine release and clearance — could produce dysfunctions amenable to KOR-targeted interventions, expanding the potential clinical relevance beyond the rare variant.
Crucially, mice with normal DAT did not show behavioral changes at the doses tested, suggesting a therapeutic window in which KOR antagonists correct abnormal dopamine handling without broadly elevating dopamine or producing side effects in healthy circuits. The treatment also improved sex-dependent behavioral differences seen in the mutant animals, indicating efficacy across both males and females in the model.
The authors emphasize that KOR antagonism might be counterproductive when dopamine dysregulation is not the underlying cause of a disorder, so careful characterization of the specific dopamine changes driving symptoms will be important for translating these findings to humans.
Overall, these preclinical results support further investigation of KOR blockers as a pharmacological strategy to treat dopamine-associated brain disorders, potentially offering a non-addictive alternative to existing dopamine-modulating therapies.
Study contributors include researchers from Florida Atlantic University, Virginia Commonwealth University, the University of North Dakota School of Medicine and Health Sciences, the University of Texas Health Science Center at San Antonio, and the University of Copenhagen, among others. The work received funding from multiple fellowships, foundations, and NIH grants as noted by the investigators.
About this neuroscience research news
Author: Gisele Galoustian
Source: FAU
Contact: Gisele Galoustian – FAU
Image: The image is credited to Neuroscience News
Original Research: Open access. “Kappa opioid receptor antagonism restores phosphorylation, trafficking and behavior induced by a disease-associated dopamine transporter variant” by Randy D. Blakely et al., published in Molecular Psychiatry.
Abstract
Kappa opioid receptor antagonism restores phosphorylation, trafficking and behavior induced by a disease-associated dopamine transporter variant
Aberrant dopamine signaling is implicated in schizophrenia, bipolar disorder, autism spectrum disorder, substance use disorder, and attention-deficit/hyperactivity disorder. Current treatments can be inadequate or carry abuse liability, motivating the search for improved, non-addictive approaches.
Using a preclinical mouse model expressing the human DAT Val559 variant — previously identified in individuals with ADHD, ASD, or bipolar disorder — the investigators examined whether targeting KOR could normalize dopamine signaling disrupted by anomalous dopamine efflux. The Val559 transporter shows constitutive changes in phosphorylation and surface trafficking that mirror KOR stimulation in wild-type DAT.
The study demonstrates that KOR antagonism rescues altered DAT phosphorylation and trafficking in ex vivo tissue and corrects in vivo dopamine release as well as sex-dependent behavioral abnormalities in DAT Val559 mice. Given the low abuse liability of KOR antagonists, these findings support further consideration of KOR blockade as a potential pharmacological strategy to treat dopamine-associated brain disorders.